New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
11:21 EDTARIA, WPX, VOLC, PVTB, PANW, IFNNY, GILD, FRX, CBST, CELG, BIIB, AMGN, ALXN, ABMD, ZLCOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) initiated with a Buy at Guggenheim... Abiomed (ABMD) initiated with a Market Perform at Raymond James... Alexion (ALXN) initiated with a Buy at Guggenheim... Amgen (AMGN) initiated with a Neutral at Guggenheim... Biogen (BIIB) initiated with a Neutral at Guggenheim... Celgene (CELG) initiated with a Buy at Guggenheim... Cubist (CBST) initiated with a Neutral at Mizuho... Forest Labs (FRX) initiated with a Buy at Mizuho... Gilead (GILD) initiated with a Buy at Guggenheim... Infineon (IFNNY) initiated with an Outperform at Bernstein... Palo Alto (PANW) initiated with a Neutral at BofA/Merrill... PrivateBancorp (PVTB) initiated with a Market Perform at Wells Fargo... Volcano (VOLC) initiated with an Outperform at Raymond James... WPX Energy (WPX) initiated with a Hold at Deutsche Bank... Zale (ZLC) initiated with a Buy at Citigroup.
News For ARIA;ABMD;ALXN;AMGN;BIIB;CELG;CBST;FRX;GILD;IFNNY;PANW;PVTB;VOLC;WPX;ZLC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
October 13, 2014
16:02 EDTGILDOptions Update; October 13, 2014
iPath S&P 500 VIX Short-Term Futures up 3.71 to 39.56. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX SUNE GILD BAC PBR according to Track Data.
10:08 EDTIFNNYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bankrate (RATE) downgraded to Equal Weight from Overweight at Stephens... CME Group (CME) downgraded to Market Perform from Outperform at Wells Fargo... Cliffs Natural (CLF) downgraded to Neutral from Overweight at JPMorgan... Dana Holding (DAN) downgraded to Sector Perform from Outperform at RBC Capital... Darden (DRI) downgraded to Neutral from Overweight at Piper Jaffray... Dover (DOV) downgraded to Neutral at RW Baird... DryShips (DRYS) downgraded to Underperform from Outperform at Imperial Capital... Infineon (IFNNY) downgraded to Neutral from Overweight at JPMorgan... J.C. Penney (JCP) downgraded to Sell from Neutral at UBS... Johnson Controls (JCI) downgraded to Outperform from Top Pick at RBC Capital... Juniper (JNPR) downgraded to Hold from Buy at Argus... Kennametal (KMT) downgraded to Market Perform from Outperform at Wells Fargo... Masco (MAS) downgraded to Equal Weight from Overweight at Barclays... New Gold (NGD) downgraded to Neutral from Overweight at JPMorgan... ON Semiconductor (ONNN) downgraded to Sector Perform from Outperform at Pacific Crest... PBF Energy (PBF) downgraded to Underweight from Equal Weight at Barclays... Parker-Hannifin (PH) downgraded to Market Perform from Outperform at Wells Fargo... STMicroelectronics (STM) downgraded to Neutral from Overweight at JPMorgan... Silicon Laboratories (SLAB) downgraded to Sector Perform at Pacific Crest... VOXX International (VOXX) downgraded to Market Perform from Outperform at Cowen.
09:56 EDTGILDBernstein biotech analyst to hold an analyst/industry conference call
Subscribe for More Information
08:36 EDTGILDGilead HARVONI launch should be strong, says BMO Capital
Subscribe for More Information
07:56 EDTGILDGilead Harvoni pricing 'very reasonable,' says RBC Capital
Subscribe for More Information
07:39 EDTGILDPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
05:28 EDTIFNNYInfineon downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
October 12, 2014
17:34 EDTPANWJPMorgan to double spending on cybersecurity over next five years, WSJ says
Subscribe for More Information
October 10, 2014
14:08 EDTGILDGilead 12-week regimen of Harvoni to cost $94.5K
Gilead said its newly-approved treatment of hepatitis C genotype 1 infection, Harvoni, will be priced at $94,500 for a full 12 week regiment, according to multiple media outlets, which cite a company spokesperson.
13:55 EDTGILDGilead confirms FDA approval of Harvoni
Subscribe for More Information
13:42 EDTGILDGilead hepatitis C treatment Harvoni approved by FDA
The FDA announced the approval of Harvoni to treat chronic hepatitis C virus genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection, the agency stated. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection, it added. Harvoni is marketed by Gilead.
13:40 EDTGILDFDA approves Gilead hepatitus C treatment Harvoni
Subscribe for More Information
12:11 EDTARIAOptions with increasing implied volatility
Subscribe for More Information
09:00 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
08:41 EDTCELGCelgene reports apremilast significantly improved preexisting psoriasis in study
Subscribe for More Information
08:39 EDTCELGCelgene says data show Apremilast treatment resulted in improved quality of life
Subscribe for More Information
08:19 EDTGILDMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
07:46 EDTARIAARIAD announces PRAC of EMA recommends Iclusig for continued EU use
Subscribe for More Information
07:21 EDTGILDFDA PDUFA Date for Gilead Sciences Sofosbuvir is October 10, 2014
Subscribe for More Information
07:14 EDTABMDJackson Square reports 12.04% passive stake in Abiomed
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use